Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-01-26
2008-08-12
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S453000, C540S466000, C540S454000
Reexamination Certificate
active
07410969
ABSTRACT:
Antitumor compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group
REFERENCES:
patent: 5089273 (1992-02-01), Rinehart et al.
patent: 5149804 (1992-09-01), Rinehart et al.
patent: 5256663 (1993-10-01), Rinehart et al.
patent: 5478932 (1995-12-01), Rinehart et al.
patent: 5654426 (1997-08-01), Rinehart et al.
patent: 5721362 (1998-02-01), Corey et al.
patent: 5985876 (1999-11-01), Rinehart et al.
patent: 6124292 (2000-09-01), Corey
patent: 6124293 (2000-09-01), Rinehart et al.
patent: 6316214 (2001-11-01), Rinehart et al.
patent: 6348467 (2002-02-01), Corey
patent: 6686470 (2004-02-01), Danishefsky et al.
patent: 6867334 (2005-03-01), Rinehart et al.
patent: 2003/0216397 (2003-11-01), Flores et al.
patent: 2004/0002602 (2004-01-01), Francesch et al.
patent: 0 309 477 (1991-11-01), None
patent: 59-225189 (1984-12-01), None
patent: 60-84288 (1985-05-01), None
patent: WO 87/07610 (1987-12-01), None
patent: WO 92/09607 (1992-06-01), None
patent: WO 98/12198 (1998-03-01), None
patent: WO 98/46080 (1998-10-01), None
patent: WO 99/51238 (1999-10-01), None
patent: WO 99/58125 (1999-11-01), None
patent: WO 00/18233 (2000-04-01), None
patent: WO 00/69862 (2000-11-01), None
patent: WO 01/77115 (2001-10-01), None
patent: WO 01/87895 (2001-11-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum, F., 20th edition,vol. 1, 1004-1010, 1996.
Valoti et al. Clin. Cancer Res. 4(8): 1977-83, 1998.
Kania, R.S. “The First Enantioselective Total Synthesis of Dolabellatrienone and Ecteinascidin 743”, Ph.D. Thesis, Harvard University, Sep. 1997, pp. 1-225.
Kubo et al., “Stereoselective Total Synthesis of (±) Saframycim B”, J. Org. Chem., vol. 53, No. 18, 1988, pp. 4295-4310.
Moore et al., “NMR-Based Model of an Ecteinascidin 743-DNA Adduct”, J/ Am. Chem. Soc., vol. 119, 1997, pp. 5475-5476.
Sparidans, R.S., et al., “Search for metabolites of ecteinascidin 743, a novel marine-derived, anti-cancer agent in man.” Anti-Cancer Drugs 2001, 12, 653-666.
Calabresi et al., “Chemotherapy of Neoplastic Diseases”, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill, 1996, pp. 1225-1229.
Cecil Textbook of Medicine (Bennet, J.C. and Plum, F., eds.) 20th Edition, vol. 1, pp. 1004-1010 (1996).
Valoti et al. Clin. Cancer Res. 4(8): 1977-83 (1998).
Fukuyama, Tohru et al., “Total Synthesis of (±)-Saframycin A”,Journal of American Chemical Society, vol. 112, pp. 3712-3713 (1990).
Garcia-Rocha, M. et al., “Characterisation of antimitotic products from marine organisms that disorganize the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15”,British Journal of Cancer, vol. 73, pp. 875-883 (1996).
Goldwasser, F, et al. “Characterization of ecteinascidin 743-induced DNA damages in cells”,Proceedings of the American Association for Cancer Research, vol. 39, #4066, pp. 598 (1998).
Guan, Yue et al., “Molecular and Crystal Structures of Ecteinascidins: Potent Antitumor Compounds from the Caribbean Tunicate Ecteinascidia Turbinata”,Journal of Biomolecular Structure&Dynamics, vol. 10, No. 5, pp. 793-818 (1993).
Gulavita, Nanda K., et al., “Antimicrobial Constituents of a Sponge-Nudibranch Pair from Sri Lanka”,Bioactive Compounds from Marine Organisms, Oxford & IBH Publishing Co. Pvt. Ltd., pp. 229-233 (1991).
He, Hai-yin et al., “Renieramycins E and F from the Sponge Reniera sp.: Reassignment of the Stereochemistry of the Renieramycins”,The Journal of Organic Chemistry, vol. 54, No. 24, pp. 5822-5824 (1989).
Hendriks, H.R. et al., “High antitumor activity of ET743 in human tumor xenograft models”,Proceedings of the American Association for Cancer Research, vol. 37, #2653, pp. 389 (1996).
Ikeda, Yoshifumi et al., “Safracins, New Antitumor Antibiotics I. Producing Organism, Fermentation and Isolation”,The Journal of Antibiotics, vol. XXXVI, No. 10, pp. 1279-1283 (1983).
Ikeda, Yoshifumi et al., “Safracins, New Antitumor Antibiotics I. Producing Organism, Fermentation and Isolation”,The Journal of Antibiotics, vol. XXXVI, No. 10, pp. 1284-1289 (1983).
Ito, Yoichiro, “High-Speed Countercurrent Chromatography”,Critical Reviews in Analytical Chemistry, vol. 17, No. 1, pp. 65-143 (1986).
Koenig, Karl E., “The Applicability of Asymmetric Homogeneous Catalytic Hodrogenation”,Asymmetric Synthesis, Ed. Morrison, Academic Press, Inc., Orlando, FL, vol. 5, pp. 71 (1985)
Kofron, William G. et al., “A Convenient Method for Estimation of Alkyllithium Concentrations”,The Journal of Organic Chemistry, vol. 41, No. 10, pp. 1879-1880 (1976).
Kubo, Akinori et al., “Structure of Saframycin D, A New Dimeric Isoquinolinequinone Antibiotic”,Chem. Pharm. Bull., vol. 35, No. 1, pp. 440-442 (1987).
Kuffel, M.J. et al., “Cytochrome P450 catalyzed metabolism of Ecteinascidin 743 by rat and human liver microsomes”,Proceedings of the American Association for Cancer Research, vol. 38, #4003, pp. 596 (1997).
Lichter, W. et al., “Biological Activities Exerted by Extracts of Ecteinascidia Turbinata”,Food and Drugs from the Sea Proceedings, pp. 117-127 (1972).
Lown, J. William et al., “Molecular Mechanisms of Binding and Single-Strand Scission of Doexyribonucleic Acid by the Antitumor Antibiotics Saframycins A and C”,Biochemistry, vol. 21, No. 3, pp. 419-428 (1982).
Lown, J. William et al., “Structure and Confirmation of Saframycin R Determined by High Field1H and13C NMR and its Interactions with DNA in Soloution”,The Journal of Antibiotics, vol. XXXVI, No. 9, pp. 1184-1194 (1983).
Rinehart, Kenneth L., “Antitumor Compounds from Tunicates”,Medicinal Research Reviews, vol. 20, No. 1, pp. 1-27 (2000).
Saito, Naoki et al., “Synthesis of Saframycins. 3. Preparation of a Key Tricyclic Lactam Intermediate to Saframycin A”,The Journal of Organic Chemistry, vol. 54, No. 22, pp. 5391-5395 (1989).
Sakai, Ryuichi et al., “Additional antitumor ecteinascidins from a Caribbean tunicate: Crystal structures and activities in vivo”,Proceedings of the National Academy of Sciences, vol. 89, No. 23, pp. 11456-11460 (1992).
Sakai, Ryuichi et al., “Ecteinascidins: Putative Biosynthetic Precursors and Absolute Stereochemistry”,Journal of the American Chemical Society, vol. 118, No. 38, pp. 9017-9023 (1996).
Shamma, Maurice et al.,Carbon-13 NMR Shift Assignments of Amines and Alkaloids, pp. 206 (1979).
Still, W. Clark et al., “Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution”,Journal of Organic Chemistry, vol. 43, No. 14, pp. 2923-2925 (1978).
Takahashi, Katsuhiro et al., “Microbial Conversion of Saframycin A to 25-Dihydrosaframycin A and 21-Decyano-25-Dihydrosaframycin A (25-Dihydrosaframycin B) and Their Biological Activities”,The Journal of Antibiotics, vol. XXXV, No. 2, pp. 196-202 (1982).
Takahashi, Katsuhiro, “New Antibiotics, Saframycins A, B, C, D and E”,The Journal of Antibiotics, vol. XXX, No. 11, pp. 1015-1018 (1977).
Trowitzsch-Kienast, Wolfram et al., “Isolierung und Strukturaufklarung der Saframycine Mx 1 und Mx 2, neue antitumor-aktive Antibiotika ausMyxococcus xanthus”, Liebigs Ann. Chem., vol. XXXV, pp. 475-481 (1988).
Witten, Jane L. et al., “Structures of Two Cockroach Neuropeptides Assigned by Fast Atom bombardment Mass Spectrometry”,Biochemical and Biophysical Research Communications, vol. 124, No. 2, pp. 350-358 (1984).
Wright, Amy E. et al., “Antitumor Tetrahydroisoquinoline Alkaloids from the Colonial Ascidian
Cuevas Carmen
Manzanares Ignacio
Martin María Jesús
Munt Simon
Perez Marta
Balasubramanian Venkataraman
Fish & Richardson P.C.
Pharma Mar S.A.
LandOfFree
Antitumoral analogs of ET-743 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antitumoral analogs of ET-743, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antitumoral analogs of ET-743 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4011948